Holen Sie sich die Stockscreener-App
1.47
0.00%
0.00
Handel nachbörslich:
1.48
0.01
+0.68%
Schlusskurs vom Vortag:
$1.47
Offen:
$1.47
24-Stunden-Volumen:
440.58K
Relative Volume:
0.46
Marktkapitalisierung:
$105.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.3238
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
+4.26%
1M Leistung:
+12.21%
6M Leistung:
-33.78%
1J Leistung:
-66.28%
1-Tages-Spanne:
$1.42
$1.48
1-Wochen-Bereich:
$1.375
$1.52
52-Wochen-Spanne:
$1.01
$5.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Vergleichen Sie ZNTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.47 | 105.77M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
How does Zentalis Pharmaceuticals Inc. compare to its industry peersUnlock powerful trading alerts for success - jammulinksnews.com
What is the dividend policy of Zentalis Pharmaceuticals Inc. stockBuild a portfolio with strong long-term growth - jammulinksnews.com
How volatile is Zentalis Pharmaceuticals Inc. stock compared to the marketMassive profits - jammulinksnews.com
What are Zentalis Pharmaceuticals Inc. company’s key revenue driversUnbelievable profit margins - jammulinksnews.com
What catalysts could drive Zentalis Pharmaceuticals Inc. stock higher in 2025Maximize your gains with professional insights - jammulinksnews.com
Will Zentalis Pharmaceuticals Inc. Stock Benefit from AI and Green Energy TrendsQuick Profit Idea Stream - Newser
Sectors Driving Future Growth for Zentalis Pharmaceuticals Inc. StockFree Access to Community - Newser
What are analysts’ price targets for Zentalis Pharmaceuticals Inc. in the next 12 monthsAchieve remarkable returns with smart investing - jammulinksnews.com
When is Zentalis Pharmaceuticals Inc. stock expected to show significant growthBoost your wealth with consistent growth stocks - jammulinksnews.com
What makes Zentalis Pharmaceuticals Inc. stock price move sharplyConsistent High Return Strategy - Newser
What drives Zentalis Pharmaceuticals Inc. stock priceFree Technical Analysis Support - PrintWeekIndia
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company - Yahoo Finance
Is Zentalis Pharmaceuticals Inc. a good long term investmentFree Technical Analysis Support - Autocar Professional
What analysts say about Zentalis Pharmaceuticals Inc. stockFree Stock Selection - Autocar Professional
Zentalis Pharmaceuticals Inc. Stock Analysis and ForecastAccelerated capital growth - Autocar Professional
Why Zentalis Pharmaceuticals Inc. stock attracts strong analyst attentionPrecision Entry Strategy - Newser
How Zentalis Pharmaceuticals Inc. stock performs during market volatilityDaily Swing Candidates - Newser
Insider Stock Buyers At Zentalis Pharmaceuticals Recouped Some Losses This Week - simplywall.st
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Wealth Enhancement Advisory Services LLC Purchases 33,958 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Zentalis Grants $1.19 Per Share Stock Options Package Under Nasdaq Compliance Rules - Stock Titan
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell Small Cap Completeness Index - MarketScreener
Zentalis Pharmaceuticals shareholders elect three directors at annual meeting - Investing.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages - Defense World
Wealth Enhancement Advisory Services LLC Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Bank of America Corp DE - Defense World
Squarepoint Ops LLC Reduces Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Ameriprise Financial Inc. Purchases New Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies - The Globe and Mail
ProShare Advisors LLC Lowers Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Why Did Zentalis Pharmaceuticals Inc. (ZNTL) Plunge 11.33%? - AInvest
Nuveen Asset Management LLC Has $1.94 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Deutsche Bank AG Grows Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Two Sigma Investments LP Sells 291,801 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Expands Cancer Research Team: 137K Share Options Granted to Key New Hires - Stock Titan
Zentalis Pharmaceuticals Presents Promising Study Results at ASCO - TipRanks
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):